Joint Effect of Hepatic Steatosis and Alanine Aminotransferase Within the Normal Range on Incident Ischemic Heart Disease: A Prospective Study in Koreans
Authors Jung DH, Lee YJ, Park B
Received 12 January 2021
Accepted for publication 8 March 2021
Published 22 March 2021 Volume 2021:16 Pages 513—523
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Nandu Goswami
Dong-Hyuk Jung,1,2 Yong Jae Lee,3,4 Byoungjin Park1
1Department of Family Medicine, Yongin Severance Hospital, Yongin-si, Gyeonggi-do, 16995, Republic of Korea; 2Department of Health Promotion Centre, Yongin Severance Hospital, Yongin-si, Gyeonggi-do, 16995, Republic of Korea; 3Department of Family Medicine, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea; 4Department of Family Medicine, Gangnam Severance Hospital, Seoul, 06273, Republic of Korea
Correspondence: Byoungjin Park
Department of Family Medicine, Yonsei University College of Medicine, Yongin Severance Hospital, 363 Dongbaekjukjeondae-Ro, Giheung-Gu, Yongin-si, Gyeonggi-do, 16995, Republic of Korea
Tel + 82 31 5189 8763
Email [email protected]
Purpose: Hepatic steatosis has been associated with some cardiovascular risks. Increased alanine aminotransferase (ALT) was suggested to be linked to endothelial dysfunction. We prospectively investigated the joint effect of hepatic steatosis and elevated ALT within the normal range on incident ischemic heart disease (IHD) risk as an extrahepatic complication.
Patients and Methods: We assessed 16,541 participants without diabetes using data from a health risk assessment study (HERAS) and Korean Health Insurance Review and Assessment (HIRA) data. We defined elevated ALT within the normal range as 30– 40 IU/L in men and 23– 40 IU/L in women, according to previous Korean epidemiological data. We prospectively assessed hazard ratios (HRs) with 95% confidence intervals (CIs) for IHD using multivariate Cox proportional hazards regression models over a 50-month period after the baseline survey.
Results: During the follow-up period, 368 (2.2%) participants developed IHD. Compared to the group with no hepatic steatosis and controlled ALT, the HRs for IHD were 1.68 (95% CI, 1.16– 2.42) in the group with hepatic steatosis and elevated ALT after adjusting for confounding variables.
Conclusion: Hepatic steatosis and elevated ALT levels within the normal range may jointly affect the development of IHD among nondiabetic adults. This indicates that lifestyle advice and vascular health management should be recommended among individuals with hepatic steatosis and elevated ALT, even if it falls within the normal range.
Keywords: hepatic steatosis, alanine aminotransferase, prospective cohort study, ischemic heart disease, extrahepatic complication
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]